Characteristics | Total (n = 427) | inv (16) (n = 176) | t (8; 21) (n = 251) | P value |
---|---|---|---|---|
Gender, n(%) | 0.715 | |||
Male | 218 (51.1%) | 88 (50.0%) | 130 (51.8%) | |
Female | 209 (48.9%) | 88 (50.0%) | 121 (48.2%) | |
Age(y), median(range) | 10.9 (0.3–17.9) | 10.6 (0.3–17.9) | 11.1 (0.6–17.8) | 0.059 |
Race | 0.002 | |||
White | 289 (77.1%) | 136 (85.0%) | 153 (71.2%) | |
Nonwhite | 86 (22.9%) | 24 (15.0%) | 62 (28.8%) | |
Ethnicity | 0.177 | |||
Hispanic or Latino | 96 (23.4%) | 34 (20.0%) | 62 (25.7%) | |
Not Hispanic or Latino | 315 (76.6%) | 136 (80.0%) | 179 (74.3%) | |
FAB Category | < 0.001 | |||
M1 | 12 (6.8%) | 0 (0.0%) | 12 (11.8%) | |
M2 | 88 (49.7%) | 0 (0.0%) | 88 (86.3%) | |
M4 | 75 (42.4%) | 74 (98.7%) | 1 (1.0%) | |
M5 | 2 (1.1%) | 1 (1.3%) | 1 (1.0%) | |
Chemotherapy protocol, n (%) | 0.387 | |||
AAML1031 | 229 (53.6%) | 90 (51.1%) | 139 (55.4%) | |
AAML0531 | 198 (46.4%) | 86 (48.9%) | 112 (44.6%) | |
Initial WBC (× 109/L), median (range) | 30.8 (0.6–478.5) | 66.5 (2.2–478.5) | 16.5 (0.6–309.3) | < 0.001 |
PB blast(%) | 42.0 (0.0–98.0) | 43.4 (0.0–94.0) | 42.0 (0.0–98.0) | 0.730 |
BM blast (%) | 59.0 (0.0–100.0) | 61.5 (6.0–100.0 | 57.0 (0.0–99.0) | 0.166 |
Risk group, n(%) | 0.703 | |||
Low risk | 419 (98.6%) | 172 (98.9%) | 247 (98.4%) | |
High risk | 6 (1.4%) | 2 (1.1%) | 4 (1.6%) | |
CNSL, n(%) | 0.066 | |||
No | 179 (42.4%) | 83 (47.7%) | 96 (38.7%) | |
Yes | 243 (57.6%) | 91 (52.3%) | 152 (61.3%) | |
Chloroma | 0.045 | |||
No | 261 (87.0%) | 111 (91.7%) | 150 (83.8%) | |
Yes | 39 (13.0%) | 10 (8.3%) | 29 (16.2%) | |
CR status at end of course 1 | 0.062 | |||
CR | 353 (84.2%) | 149 (86.6%) | 204 (82.6%) | |
Not in CR | 59 (14.1%) | 18 (10.5%) | 41 (16.6%) | |
Death | 7 (1.7%) | 5 (2.9%) | 2 (0.8%) | |
CR status at end of course 2 | 0.441 | |||
CR | 394 (95.2%) | 158 (94.0%) | 236 (95.9%) | |
Not in CR | 8 (1.9%) | 5 (3.0%) | 3 (1.2%) | |
Death | 12 (2.9%) | 5 (3.0%) | 7 (2.8%) | |
GO treatment | 0.586 | |||
No | 56 (50.9%) | 21 (47.7%) | 35 (53.0%) | |
Yes | 54 (49.1%) | 23 (52.3%) | 31 (47.0%) | |
Bone Marrow Site of Relapse | 0.049 | |||
No | 341 (73.5%) | 137 (68.8%) | 204 (77.0%) | |
Yes | 123 (26.5%) | 62 (31.2%) | 61 (23.0%) | |
CNS Site of Relapse | < 0.001 | |||
No | 436 (94.0%) | 177 (88.9% | 259 (97.7%) | |
Yes | 28 (6.0%) | 22 (11.1%) | 6 (2.3%) | |
Other Site of Relapse | 0.704 | |||
No | 458 (98.7%) | 197 (99.0%) | 261 (98.5%) | |
Yes | 6 (1.3%) | 2 (1.0%) | 4 (1.5%) |